[转移性乳腺癌患者接受sacituzmab govitecan治疗后的长期生存率]

Q3 Medicine

Recenti progressi in medicina Pub Date : 2024-10-01 DOI:10.1701/4357.43484

Carlo Mulas, Luigi Mascia

{"title":"[转移性乳腺癌患者接受sacituzmab govitecan治疗后的长期生存率]","authors":"Carlo Mulas, Luigi Mascia","doi":"10.1701/4357.43484","DOIUrl":null,"url":null,"abstract":"The clinical case presented refers to a woman suffering from metastatic breast cancer treated with sacituzumab govitecan (SG) who has a long progression-free survival. The case is characterized by the extreme aggressiveness of the neoplastic disease that relapses during adjuvant hormonal treatment with a metastatic disease that presents immunohistochemical characteristics different from the primary tumor. After first-line therapy with nabpaclitaxel and atezolizumab and the subsequent one with carboplatin and gemcitabine, both characterized by short PFS, the third line with SG is characterized by obtaining a complete response and a prolonged PFS as well as extreme tolerability that continues to this day after 15 months of treatment.","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"72e-76e"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Long term survival in patient with metastatic breast cancer treated with sacituzmab govitecan.]\",\"authors\":\"Carlo Mulas, Luigi Mascia\",\"doi\":\"10.1701/4357.43484\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The clinical case presented refers to a woman suffering from metastatic breast cancer treated with sacituzumab govitecan (SG) who has a long progression-free survival. The case is characterized by the extreme aggressiveness of the neoplastic disease that relapses during adjuvant hormonal treatment with a metastatic disease that presents immunohistochemical characteristics different from the primary tumor. After first-line therapy with nabpaclitaxel and atezolizumab and the subsequent one with carboplatin and gemcitabine, both characterized by short PFS, the third line with SG is characterized by obtaining a complete response and a prolonged PFS as well as extreme tolerability that continues to this day after 15 months of treatment.\",\"PeriodicalId\":20887,\"journal\":{\"name\":\"Recenti progressi in medicina\",\"volume\":\"115 10\",\"pages\":\"72e-76e\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recenti progressi in medicina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1701/4357.43484\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4357.43484","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

本临床病例指的是一名患有转移性乳腺癌的妇女，她曾接受过萨库珠单抗-戈维替康（SG）治疗，并获得了较长的无进展生存期。该病例的特点是肿瘤疾病具有极强的侵袭性，在激素辅助治疗期间复发，转移性疾病呈现出不同于原发肿瘤的免疫组化特征。经过纳帕紫杉醇和阿特珠单抗的一线治疗，以及卡铂和吉西他滨的二线治疗后，二者的生存期都很短，而使用 SG 的三线治疗的特点是获得了完全应答，延长了生存期，并且在治疗 15 个月后的今天仍具有极高的耐受性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Long term survival in patient with metastatic breast cancer treated with sacituzmab govitecan.]

The clinical case presented refers to a woman suffering from metastatic breast cancer treated with sacituzumab govitecan (SG) who has a long progression-free survival. The case is characterized by the extreme aggressiveness of the neoplastic disease that relapses during adjuvant hormonal treatment with a metastatic disease that presents immunohistochemical characteristics different from the primary tumor. After first-line therapy with nabpaclitaxel and atezolizumab and the subsequent one with carboplatin and gemcitabine, both characterized by short PFS, the third line with SG is characterized by obtaining a complete response and a prolonged PFS as well as extreme tolerability that continues to this day after 15 months of treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Recenti progressi in medicina Medicine-Medicine (all)

CiteScore

0.90

自引率

0.00%

发文量

143

期刊介绍： Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.